Pediatrics

With these findings contributing to the understanding of neighborhood-level asthma risks, the authors note next steps can involve identifying and addressing disparities.

The results reinforce other real-world evidence from several broad infant immunization programs in the US, Spain, and France.

The acceptance is based on positive data from the phase 3 ADORING 1 and ADORING 2 pivotal trials, as well as interim results from the phase 3 ADORING 3 open-label, long-term extension trial.

Retail sales were associated with lower e-cigarette use, although recreational legalization also increased the frequency of cannabis use among adolescents.

The indication is for patients aged 12 years of age and older, and the treatment is intended to increase the number of mature neutrophils and lymphocytes in patients.

This approval makes lutetium Lu177 the first therapy to be approved for the treatment of gastroenteropancreatic neuroendocrine tumors in pediatric patients.

The treatment is indicated for adolescents at least 12 years of age who weigh at least 25 kg without a previous treatment history of antiretroviral therapies.

Pediatric patients with the variant were approximately 1.44 times more likely develop ALL compared with children who do not have the variant.

The authors believe that pancreatic enzyme therapy has potential in managing patient symptoms, altering the disease course, and the development of standardized care.

The FDA recommends the dosage of givinostat (Duvyzat; Italfarmaco, ITF Therapeutics) should be based on the individual’s body weight and administered twice daily with food.

Rilpivirine (Edurant Ped; Johnson and Johnson) is indicated for the treatment of HIV in combination with other antiretroviral therapies in treatment-naïve pediatric patients.

Regardless, hygiene practices and prevention measures for SARS-CoV-2 should be strongly practiced to prevent all respiratory viruses.

To date, this is the only targeted therapy indicated for the treatment of generalized pustular psoriasis.

The FDA-approved topical and oral agent is currently indicated for adult patients with patterned alopecia.

The drug is indicated for patients 5 years of age and older with progressive familial intrahepatic cholestasis and cholestatic pruritus in pediatric patients with Alagille syndrome.

The findings suggest that ruxolitinib cream could aid itch, pain, and sleep disturbance.

Findings emphasize the importance of further research on effective and safe alternative treatments for MDD in children and adolescents, specifically in patients who are refractory to nonpharmacologic treatment and/or standard of care antidepressants

Children with normal weight had different community relationships compared to children with overweight or obesity.

There have been ongoing concerns about the long-term effects of prenatal exposure on neurodevelopment.

These experiences can impact mental health, which can mediate parenting behaviors like inconsistent discipline.

The practice could become routine if parents promote morning vegetable consumption while the children are still in a developmental stage of life.

Community pharmacists are in a unique position to counsel caregivers on liquid children’s products

RSV can exacerbate asthma development by causing damage to the tissue in the airways, promoting inflammation and increasing airway hyper-responsiveness

Children with heart disease who received infant open-heart surgery had more stress and neurodevelopmental impairments compared with children who did not undergo surgery.

The FDA approval marks the first and only FDA-approved oral therapy for this patient population, and the drug is expected to be available by the end of February.

Between 2018 and 2021, kindergarten-readiness dropped by 10%.

Early signs of psychosis may be used to predict the risk of developing a full psychosis spectrum disorder.

These heat-not-burn cigarettes are incorrectly assumed to be healthier than traditional tobacco cigarettes.

Be of value to patients and caregivers in forming a care plan for this challenging condition

The approval marks dupilumab as the first and only FDA-approved medicine to treat pediatric patients with eosinophilic esophagitis.